Late-onset Familial Hemophagocytic Lymphohistiocytosis in a survivor of Hodgkin's Lymphoma
Leuk Res Rep. 2023 Nov 7;21:100394. doi: 10.1016/j.lrr.2023.100394. eCollection 2024.ABSTRACTHemophagocytic Lymphohistiocytosis is an inflammatory condition which results in over activation of the immune system. It could be either sporadic or familial. The familial subtype is linked with various genetic mutations and is commonly a disease of the young. Here we report a case of HLH in an adult, occurring in the background of a successfully treated hematological malignancy. Upon workup, he was also found to have pathogenic STXBP2 mutation, suggesting HLH of familial origin. To date, only few cases of adult-onset familial HLH...
Source: Cell Research - April 17, 2024 Category: Cytology Authors: Mirza Rameez Samar Daania Shoaib Nida E Zehra Munira Moosajee Source Type: research
Outcomes of the transformation of follicular lymphoma to diffuse large B ‐cell lymphoma in the rituximab era: A population‐based study
ConclusionThe outcome of t-DLBCL in the rituximab era was better than historical series before the rituximab era. Due to the good prognosis, we did not recommend autologous stem cell transplantation for t-DLBCL receiving watch-and-wait or radiation as initial therapy before HT. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Wenshuai Zheng,
Mingjuan Liu,
Lixun Guan,
Shenyu Wang Tags: RESEARCH ARTICLE Source Type: research
GSE260998 Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma – Visium_FFPE_Spatial_Trasciptomics_project
This study provides novel insights into signals controlling asymmetric T-cell distribution between DZ and LZ regions. We identify spatially-resolved DNA damage response and chromatin compaction molecular features precluding DZ T-cell infiltration. The DZ spatial transcriptional signature linked to T-cell immune evasion clustered aggressive Diffuse Large B-cell Lymphomas (DLBCL) for differential T cell infiltration. We reveal the dependence of the DZ transcriptional core signature on the ATR kinase and dissect its role in restraining inflammatory responses contributing to estabslish an immune-repulsive imprint in DLBCL. The...
Source: GEO: Gene Expression Omnibus - April 17, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
GSE252480 Germinal Center Cytokines Driven Epigenetic Control of Epstein-Barr Virus Latency Gene Expression
Contributors : Yifei Liao ; Jinjie Yan ; Nina R Beri ; Lisa Giulino-Roth ; Ethel Cesarman ; Benjamin GewurzSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensEpstein-Barr virus (EBV) persistently infects 95% of adults worldwide and is associated with multiple human lymphomas that express characteristic EBV latency programs used by the virus to navigate the B-cell compartment. Upon primary infection, the EBV latency III program, comprised of six Epstein-Barr Nuclear Antigens (EBNA) and two Latent Membrane Protein (LMP) antigens, drives infected B-cells into germinal center (GC). By i...
Source: GEO: Gene Expression Omnibus - April 17, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
A germline point mutation in the MYC-FBW7 phosphodegron initiates hematopoietic malignancies [Research Papers]
Oncogenic activation of MYC in cancers predominantly involves increased transcription rather than coding region mutations. However, MYC-dependent lymphomas frequently acquire point mutations in the MYC phosphodegron, including at threonine 58 (T58), where phosphorylation permits binding via the FBW7 ubiquitin ligase triggering MYC degradation. To understand how T58 phosphorylation functions in normal cell physiology, we introduced an alanine mutation at T58 (T58A) into the endogenous c-Myc locus in the mouse germline. While MYC-T58A mice develop normally, lymphomas and myeloid leukemias emerge in ~60% of adult homozygous T...
Source: Genes and Development - April 17, 2024 Category: Genetics & Stem Cells Authors: Freie, B., Carroll, P. A., Varnum-Finney, B. J., Ramsey, E. L., Ramani, V., Bernstein, I., Eisenman, R. N. Tags: Research Papers Source Type: research
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs
CONCLUSION: In this case, the first ALK resistance mutation detected after progression on first line TKI, the I1171N, is a common resistance mutation after alectinib and confers sensitivity to brigatinib, that the patient received afterwards with a long-term disease stability. The second ALK resistance mutation detected after a chemotherapy interval, the G1202R, is the most common resistance mutation after second generation ALK TKIs and has been associated with sensitivity to third generation TKIs, such as lorlatinib. This case of a patient with EML4-ALK-rearranged NSCLC shows that sequential treatment with next-generation...
Source: Tumori - April 16, 2024 Category: Cancer & Oncology Authors: Rita Leporati Daniela Miliziano Teresa Beninato Laura Mazzeo Sara Manglaviti Marta Brambilla Mario Occhipinti Arsela Prelaj Claudia Proto Giuseppe Lo Russo Source Type: research
Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
CONCLUSION: Our data indicate that if aggressive lymphoid neoplasms develop during the course of treatment in patients with MPNs, it is acceptable to prioritize chemotherapy for lymphoma.PMID:38626148 | DOI:10.1080/16078454.2024.2340149 (Source: Hematology)
Source: Hematology - April 16, 2024 Category: Hematology Authors: Yoko Edahiro Tomonori Ochiai Yoshinori Hashimoto Michiko Ichii Takeshi Okatani Hiromi Omura Kei Nakajima Makoto Sasaki Jun Ando Tomoiku Takaku Michiaki Koike Koh Izumiyama Junji Hiraga Tomofumi Yano Kensuke Usuki Eiichi Ohtsuka Kenji Yokoyama Tatsuo Oyake Source Type: research
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs
CONCLUSION: In this case, the first ALK resistance mutation detected after progression on first line TKI, the I1171N, is a common resistance mutation after alectinib and confers sensitivity to brigatinib, that the patient received afterwards with a long-term disease stability. The second ALK resistance mutation detected after a chemotherapy interval, the G1202R, is the most common resistance mutation after second generation ALK TKIs and has been associated with sensitivity to third generation TKIs, such as lorlatinib. This case of a patient with EML4-ALK-rearranged NSCLC shows that sequential treatment with next-generation...
Source: Tumori - April 16, 2024 Category: Cancer & Oncology Authors: Rita Leporati Daniela Miliziano Teresa Beninato Laura Mazzeo Sara Manglaviti Marta Brambilla Mario Occhipinti Arsela Prelaj Claudia Proto Giuseppe Lo Russo Source Type: research
Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [ < sup > 18 < /sup > F]FDG-PET/CT and bone marrow biopsy findings
CONCLUSION: In AITL patients, PET/BM-positive results may obviate the necessity for repeat BMB to ascertain confirm BM involvement. PET/BM-negative results do not definitively exclude BM involvement. The combined use of [18F]FDG-PET/CT and BMB can increase the diagnostic accuracy of BM involvement for AITL patients.PMID:38626218 | DOI:10.1080/03007995.2024.2337670 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - April 16, 2024 Category: Research Authors: Xinyu Liang Chunli Yang Minggang Su Liqun Zou Source Type: research
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
Clin Lymphoma Myeloma Leuk. 2024 Mar 22:S2152-2650(24)00112-5. doi: 10.1016/j.clml.2024.03.005. Online ahead of print.ABSTRACTImmunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therap...
Source: Clinical Lymphoma and Myeloma - April 16, 2024 Category: Cancer & Oncology Authors: Noopur S Raje Adam D Cohen Krina K Patel Niels W C J van de Donk Joshua Richter Jesus San-Miguel Source Type: research
Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [ < sup > 18 < /sup > F]FDG-PET/CT and bone marrow biopsy findings
CONCLUSION: In AITL patients, PET/BM-positive results may obviate the necessity for repeat BMB to ascertain confirm BM involvement. PET/BM-negative results do not definitively exclude BM involvement. The combined use of [18F]FDG-PET/CT and BMB can increase the diagnostic accuracy of BM involvement for AITL patients.PMID:38626218 | DOI:10.1080/03007995.2024.2337670 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - April 16, 2024 Category: Research Authors: Xinyu Liang Chunli Yang Minggang Su Liqun Zou Source Type: research
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
J Natl Compr Canc Netw. 2024 Apr;22(3):175-204. doi: 10.6004/jnccn.2024.0018.ABSTRACTChronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 16, 2024 Category: Cancer & Oncology Authors: William G Wierda Jennifer Brown Jeremy S Abramson Farrukh Awan Syed F Bilgrami Greg Bociek Danielle Brander Matthew Cortese Larry Cripe Randall S Davis Herbert Eradat Bita Fakhri Christopher D Fletcher Sameh Gaballa Muhammad Saad Hamid Brian Hill Paul Kae Source Type: research
Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
CONCLUSION: Our data indicate that if aggressive lymphoid neoplasms develop during the course of treatment in patients with MPNs, it is acceptable to prioritize chemotherapy for lymphoma.PMID:38626148 | DOI:10.1080/16078454.2024.2340149 (Source: Hematology)
Source: Hematology - April 16, 2024 Category: Hematology Authors: Yoko Edahiro Tomonori Ochiai Yoshinori Hashimoto Michiko Ichii Takeshi Okatani Hiromi Omura Kei Nakajima Makoto Sasaki Jun Ando Tomoiku Takaku Michiaki Koike Koh Izumiyama Junji Hiraga Tomofumi Yano Kensuke Usuki Eiichi Ohtsuka Kenji Yokoyama Tatsuo Oyake Source Type: research
BCL2A1 neoepitopes-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer
J Leukoc Biol. 2024 Apr 16:qiae092. doi: 10.1093/jleuko/qiae092. Online ahead of print.ABSTRACTConventional treatments have shown a limited efficacy for pancreatic cancer, and immunotherapy is an emerging option for treatment of this highly fatal malignancy. Neoantigen is critical to improving the efficacy of tumor-specific immunotherapy. The cancer and peripheral blood specimens from human leukocyte antigen (HLA)-A0201 positive pancreatic cancer patient were subjected to next-generation sequencing and bioinformatics analyses were performed to screen high-affinity and highly stable neoepitopes. The activation of cytotoxic ...
Source: Journal of Leukocyte Biology - April 16, 2024 Category: Hematology Authors: Shengzhe Lin Jingwen Hong Suxin Wu Chenlu Zhu Fang Liu Wansong Lin Xinran Cai Yunbin Ye Yanling Chen Source Type: research
